Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01920854 · ClinicalTrials.gov registry record · Phase 1
A Single Ascending Dose Study of Soluble Ferric Pyrophosphate Administered Intravenously in Healthy Volunteers.
A Phase 1 study of Kidney Failure, Chronic Therapy; Hemodialysis, sponsored by Rockwell Medical Technologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT01920854 is a Phase 1 study of Kidney Failure, Chronic Therapy; Hemodialysis that has completed, run by Rockwell Medical Technologies. The registered enrollment target is 48 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01920854, a Phase 1 study of Kidney Failure, Chronic Therapy; Hemodialysis, has completed, sponsored by Rockwell Medical Technologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the pharmacokinetics of fixed ascending doses of intravenously administered Soluble Ferric Pyrophosphate
Conditions Studied
Interventions
- DRUG Placebo
- DRUG soluble ferric pyrophosphate
Study Locations (1)
Michigan
- - Kalamazoo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2013-06 |
| Est. Completion | 2013-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01920854
The ClinicalTrials.gov registry entry for NCT01920854 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rockwell Medical Technologies, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kidney Failure, Chronic Therapy; Hemodialysis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01920854 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT01920854 about?
NCT01920854 is a clinical study titled "A Single Ascending Dose Study of Soluble Ferric Pyrophosphate Administered Intravenously in Healthy Volunteers.". The purpose of this study is to determine the pharmacokinetics of fixed ascending doses of intravenously administered Soluble Ferric Pyrophosphate
What is the current status of trial NCT01920854?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2013-06. Estimated completion is 2013-09.
What conditions does trial NCT01920854 study?
This clinical trial studies the following conditions: Kidney Failure, Chronic Therapy; Hemodialysis.
What interventions are being tested in trial NCT01920854?
The interventions under investigation include: Placebo (DRUG), soluble ferric pyrophosphate (DRUG).
Who is sponsoring clinical trial NCT01920854?
This trial is sponsored by Rockwell Medical Technologies, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01920854 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.